全文获取类型
收费全文 | 16702篇 |
免费 | 1338篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 147篇 |
儿科学 | 543篇 |
妇产科学 | 322篇 |
基础医学 | 2315篇 |
口腔科学 | 270篇 |
临床医学 | 1625篇 |
内科学 | 3640篇 |
皮肤病学 | 175篇 |
神经病学 | 1346篇 |
特种医学 | 664篇 |
外科学 | 2830篇 |
综合类 | 271篇 |
一般理论 | 20篇 |
预防医学 | 1457篇 |
眼科学 | 400篇 |
药学 | 1027篇 |
1篇 | |
中国医学 | 14篇 |
肿瘤学 | 1017篇 |
出版年
2023年 | 79篇 |
2022年 | 132篇 |
2021年 | 309篇 |
2020年 | 204篇 |
2019年 | 321篇 |
2018年 | 432篇 |
2017年 | 289篇 |
2016年 | 304篇 |
2015年 | 349篇 |
2014年 | 515篇 |
2013年 | 692篇 |
2012年 | 1185篇 |
2011年 | 1150篇 |
2010年 | 649篇 |
2009年 | 570篇 |
2008年 | 1005篇 |
2007年 | 1072篇 |
2006年 | 1073篇 |
2005年 | 1024篇 |
2004年 | 1004篇 |
2003年 | 939篇 |
2002年 | 895篇 |
2001年 | 194篇 |
2000年 | 189篇 |
1999年 | 194篇 |
1998年 | 189篇 |
1997年 | 188篇 |
1996年 | 161篇 |
1995年 | 128篇 |
1994年 | 127篇 |
1993年 | 136篇 |
1992年 | 109篇 |
1991年 | 141篇 |
1990年 | 90篇 |
1989年 | 108篇 |
1988年 | 107篇 |
1987年 | 97篇 |
1986年 | 113篇 |
1985年 | 86篇 |
1984年 | 98篇 |
1983年 | 112篇 |
1982年 | 104篇 |
1981年 | 107篇 |
1980年 | 94篇 |
1979年 | 112篇 |
1978年 | 88篇 |
1977年 | 69篇 |
1976年 | 60篇 |
1975年 | 77篇 |
1974年 | 64篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
Smith DR Weinstock-Guttman B Cohen JA Wei X Gutmann C Bakshi R Olek M Stone L Greenberg S Stuart D Orav J Stuart W Weiner H 《Multiple sclerosis (Houndmills, Basingstoke, England)》2005,11(5):573-582
OBJECTIVE: To evaluate the efficacy and safety of combination therapy with pulse cyclophosphamide given with methylprednisolone (MP) and interferon beta (IFNbeta)-Ia in multiple sclerosis (MS) patients with active disease during IFNbeta monotherapy. METHODS: This was a randomized, single-blind, parallel-group, multicenter trial in MS patients with a history of active disease during IFNbeta treatment. Patients were randomized to either cyclophosphamide 800 mg/m2 plus methylprednisolone 1 g IV (CY/MP) or methylprednisolone once a month for six months and then followed for an additional 18 months. All patients received three days of methylprednisolone 1 g IV at screening and 30 mcg IFNbeta-Ia IM weekly for the entire 24 months. The primary endpoint was change from baseline in the mean number of gadolinium-enhancing (Gd+) lesions. Secondary clinical endpoints included time to treatment failure. RESULTS: Fifty-nine patients were randomized to treatment: 30 to CY/MP and 29 to MP Change from baseline in the number of Gd+ lesions was significantly different between treatment groups at three (P =0.01), six (P =0.04) and 12 months (P =0.02), with fewer lesions in the CY/MP group. The cumulative rate of treatment failure was significantly lower in the CY/MP group compared with the MP group (rate ratio =0.30; 95% confidence interval, 0.12-0.75; P =0.011). CY/MP treatment was well tolerated. CONCLUSION: Combination therapy with CY/MP and IFNbeta-Ia decreased the number of Gd+ lesions and slowed clinical activity in patients with previously active disease on IFNbeta alone. 相似文献
972.
Genetics of osteoporosis 总被引:1,自引:0,他引:1
Genetic factors play an important role in regulating bone mineral density and other phenotypes relevant to the pathogenesis
of osteoporosis such as ultrasound properties of bone, skeletal geometry, and bone turnover. Progress has been made in identifying
quantitative traits for regulation of bone mineral density by linkage studies in man and mouse, but relatively few causal
genes have been identified. Dramatic progress has been made in identifying the genes responsible for monogenic bone diseases
and it appears that polymorphisms in many of these genes also play a role in regulating bone mineral density in the general
population. Advances in knowledge about the genetic basis of osteoporosis and other bone diseases offer the prospect of developing
new markers for assessment of fracture risk and the identification of novel molecular targets for the design of new drug treatments
for osteoporosis. 相似文献
973.
Lipton SA 《Current Alzheimer research》2005,2(2):155-165
In western countries, Alzheimer's disease (AD) is the most common form of dementia. In fact, if left uncurbed, the economic cost of caring for AD patients could consume the entire gross national product of the USA by the middle of this century. Until recently, the only available drugs for this condition were cholinergic treatments, which symptomatically enhance cognitive state to some degree, but they were not neuroprotective. In fact, many potential neuroprotective drugs tested in clinical trials failed because they were poorly tolerated. However, after our discovery of its clinically-tolerated mechanism of action, one neuroprotective drug, memantine, was recently approved by the European Union and the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease. Recent phase 3 clinical trials have shown that memantine is effective in the treatment of both mild and moderate-to-severe Alzheimer's disease and possibly vascular dementia (multi-infarct dementia). Here we review the molecular mechanism of memantine's action and also the basis for the drug's use in these neurological diseases, which are mediated at least in part by excitotoxicity. Excitotoxicity is defined as excessive exposure to the neurotransmitter glutamate or overstimulation of its membrane receptors, leading to neuronal injury or death. Excitotoxic neuronal cell death is mediated in part by overactivation of N-methyl-d-aspartate (NMDA)-type glutamate receptors, which results in excessive Ca2+ influx through the receptor's associated ion channel. Physiological NMDA receptor activity, however, is also essential for normal neuronal function. This means that potential neuroprotective agents that block virtually all NMDA receptor activity will very likely have unacceptable clinical side effects. For this reason many previous NMDA receptor antagonists have disappointingly failed advanced clinical trials for a number of neurodegenerative disorders. In contrast, studies in our laboratory have shown that the adamantane derivative, memantine, preferentially blocks excessive NMDA receptor activity without disrupting normal activity. Memantine does this through its action as an uncompetitive, low-affinity, open-channel blocker; it enters the receptor-associated ion channel preferentially when it is excessively open, and, most importantly, its off-rate is relatively fast so that it does not substantially accumulate in the channel to interfere with normal synaptic transmission. Clinical use has corroborated the prediction that memantine is thus well tolerated. Besides Alzheimer's disease, memantine is currently in trials for additional neurological disorders, including other forms of dementia, depression, glaucoma, and severe neuropathic pain. A series of second-generation memantine derivatives are currently in development and may prove to have even greater neuroprotective properties than memantine. These second-generation drugs take advantage of the fact that the NMDA receptor has other modulatory sites in addition to its ion channel that potentially could also be used for safe but effective clinical intervention. 相似文献
974.
Harmatz P Ketteridge D Giugliani R Guffon N Teles EL Miranda MC Yu ZF Swiedler SJ Hopwood JJ;MPS VI Study Group 《Pediatrics》2005,115(6):e681-e689
975.
976.
Tsalikian E Mauras N Beck RW Tamborlane WV Janz KF Chase HP Wysocki T Weinzimer SA Buckingham BA Kollman C Xing D Ruedy KJ;Diabetes Research In Children Network Direcnet Study Group 《The Journal of pediatrics》2005,147(4):528-534
OBJECTIVE: To examine the effect of exercise on overnight hypoglycemia in children with type 1 diabetes mellitus (T1DM). STUDY DESIGN: At 5 clinical sites, 50 subjects with T1DM (age 11 to 17 years) were studied in a clinical research center on 2 separate days. One day included an afternoon exercise session on a treadmill. On both days, frequently sampled blood glucose levels were measured at the DirecNet central laboratory. Insulin doses were similar on both days. RESULTS: During exercise, plasma glucose levels fell in almost all subjects; 11 (22%) developed hypoglycemia. Mean glucose level from 10 pm to 6 am was lower on the exercise day than on the sedentary day (131 vs 154 mg/dL; P=.003). Hypoglycemia developed overnight more often on the exercise nights than on the sedentary nights (P=.009), occurring on the exercise night only in 13 (26%), on the sedentary night only in 3 (6%), on both nights in 11 (22%), and on neither night in 23 (46%). Hypoglycemia was unusual on the sedentary night if the pre-bedtime snack glucose level was>130 mg/dL. CONCLUSIONS: These findings indicate that overnight hypoglycemia after exercise is common in children with T1DM and support the importance of modifying diabetes management after afternoon exercise to reduce the risk of hypoglycemia. 相似文献
977.
Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans 总被引:3,自引:0,他引:3
Price VE Fletcher JA Zielenska M Cole W Viero S Manson DE Stuart M Pappo AS 《Pediatric blood & cancer》2005,44(5):511-515
To document the clinical activity of imatinib mesyalte in a child with a dermatofibrosarcoma protuberans (DFSP). An 18-month-old girl presented with a large extremity DFSP. As surgical resection would have caused unacceptable functional defects, imatinib mesylate was administered to induce tumor reduction and or stabilization. After 23 weeks of therapy, magnetic resonance imaging (MRI) of the tumor showed a reduction in the subcutaneous thickness in the transverse plane. The drug was tolerated well without any adverse reactions. Imatinib mesylate offers a non-surgical alternative for the treatment of large DFSP in children. 相似文献
978.
OBJECTIVE: To delineate the personal, psychosocial, and disease-related factors that may influence rheumatoid arthritis (RA) patients' decisions to participate in clinical trials. METHODS: A total of 191 patients with RA were asked to participate in this survey. The questionnaire collected information on demographics, RA disease-related factors, and the importance of several factors that might influence patients' willingness to participate in clinical trials. Patients were then asked if they would consider participating in a hypothetical study. RESULTS: Participants were 88% female with a mean age of 40.5 years. The ethnic composition was 57% Hispanic, 25% Caucasian, 12% Asian, and 6% African American, with 71% having a family income < $20,000/year. Factors that patients considered important for participation in a clinical study included: the opportunity to help others, the possibility of improved health, early access to new therapy, the availability of free treatments, unknown side effects of the study drug, and the need to stop current therapy. There were strong correlations between the rank order importance weights between Hispanics and Caucasians, suggesting fundamental similarities in preferences. The most important factor was the opportunity to help others. In general, the more important factors were associated with preferences for trial participation. CONCLUSION: This questionnaire identified factors that may affect RA patients' willingness to participate in a study. Patient participation in trials is driven by diverse factors that include altruism and the opportunity for healthcare and improved health. Consideration of these factors may facilitate the inclusion of more diverse patient populations into trials and enhance the applicability of trial results. 相似文献
979.
Lonser RR Walbridge S Murray GJ Aizenberg MR Vortmeyer AO Aerts JM Brady RO Oldfield EH 《Annals of neurology》2005,57(4):542-548
Systemic enzyme replacement for Gaucher's disease has not prevented premature death or severe morbidity in patients with a neuronopathic phenotype, because the enzyme does not cross the blood-brain barrier. We used convection-enhanced delivery for regional distribution of glucocerebrosidase in rat and primate brains and examined its safety and feasibility for neuronopathic Gaucher's disease. Rats underwent intrastriatal infusion and were observed and then sacrificed at 14 hours, 4 days, or 6 weeks. Primates underwent serial magnetic resonance imaging during enzyme perfusion of the right frontal lobe or brainstem, were observed and then sacrificed after infusion completion. Animals underwent histologic and enzymatic tissue analyses. Magnetic resonance imaging revealed perfusion of the primate right frontal lobe or pons with infusate. Enzyme activity was substantially and significantly (p < 0.05) increased in cortex and white matter of the infused frontal lobe and pons compared to control. Immunohistochemistry demonstrated intraneuronal glucocerebrosidase. There was no toxicity. Convection-enhanced delivery can be used to safely perfuse large regions of the brain and brainstem with therapeutic levels of glucocerebrosidase. Patients with neuronopathic Gaucher's disease and similar central nervous system disorders may benefit from this treatment. 相似文献
980.
Uniparental disomy is a genetic cause of disease implicated in a wide variety of neurologic disorders. A recently identified condition is maternal uniparental disomy for chromosome 14 (mUPD14) syndrome. A child with hypotonia and developmental delay was found to have mUPD14 after identification of a balanced karyotypic rearrangement involving both chromosomes 14. We explore the genetic mechanisms by which uniparental disomy can cause clinical abnormalities and karyotypic findings that should raise suspicion for uniparental disomy, review the literature on the mUPD14, and discuss clinical indications on which to suspect this diagnosis. Although it is more difficult to establish a diagnosis in the absence of visible karyotypic abnormalities involving chromosome 14, a distinct phenotype exists in mUPD14 syndrome: in utero growth restriction, congenital hypotonia, gross motor delay, arrested hydrocephalus, mild to moderate mental retardation, joint hyperextensibility, short stature, and precocious puberty. Testing for mUPD14 should be considered in infants with generalized hypotonia who have a history of in utero growth restriction. 相似文献